Clinical trial

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Cybin IRL LimitedRecruitingPhase 3Started Dec 10, 2025330 enrolledUnited States, Australia, Czechia, Germany, Greece, Ireland, Poland, United KingdomNCT06793397

Abstract

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinDepression

Keywords

MDDPsychedelicMajor Depressive DisorderCYB003CYB003-001CYB003-002psilocin-7438Major Depressive Disorder (MDD)Depression in AdultsDepression - Major Depressive DisorderDepression DisordersDepression Disorder

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticlePsilocybin

Association of Psilocybin Use in Adolescents with Major Depressive Episode

Shah K, Trivedi C, Kamrai D +2

Europe PMC2022

ArticlePsilocybin

Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.

Haridy R

Europe PMC2023

ArticlePsilocybin

Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in <i>Gymnopilus dilepis</i> Mushroom via Amino Acid Metabolism Pathways.

Yao S, Wei C, Lin H +5

Europe PMC2022